RxDoctor Payments Data

Paul Cohen, MD

Internal Medicine · Myrtle Beach, SCNPI 1194778423

Payments from drug & device makers

$622in general payments, 2019–2025

Across 20 payments — averaging $31.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$132
  • Inari Medical, Inc.$119
  • AstraZeneca$109
  • AbbVie$65
  • Amgen$32
  • Mylan Specialty L.p.$29
  • plus $136 from 7 others

What the payments were for

  • Food & beverage$622100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$622 in reported general payments places this provider in the 60th percentile of 1,498 internal medicine providers in South Carolina.

See all internal medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$1,094
Medicare patients
35
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$49,787
OzempicSemaglutide18$23,728
XareltoRivaroxaban16$22,794
JanuviaSitagliptin Phosphate14$19,296
RybelsusSemaglutide16$16,613
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$16,327
FarxigaDapagliflozin Propanediol12$9,723
Combivent RespimatIpratropium/Albuterol Sulfate11$6,141
Albuterol Sulfate HfaAlbuterol Sulfate48$3,368
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$3,324
Omeprazole121$2,233
Ventolin HfaAlbuterol Sulfate17$2,145
Atorvastatin Calcium202$1,803
Gabapentin62$1,430
SynthroidLevothyroxine Sodium11$938

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$49,78736 claims
Novo NordiskOzempic, Rybelsus$24$40,34134 claims
MerckJanuvia$16$19,29614 claims
GSKTrelegy Ellipta$132$16,32718 claims
AstraZenecaFarxiga$109$9,72312 claims
AbbVieSynthroid$65$93811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,498 internal medicine providers in South Carolina.

Other internal medicine in Myrtle Beach

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →